FGAM
BMRN icon

Financial Gravity Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Financial Gravity Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24
Closed -$2.18K – 1560
2024
Q1 		$2.18K Sell
24
-2
-8% -$179 ﹤0.01% 1063
2023
Q4 		$2.74K Buy
26
+13
+100% +$1.15K ﹤0.01% 942
2023
Q3 		$1.25K Sell
13
-74
-85% -$6.58K ﹤0.01% 743
2023
Q2 		$1.1K Sell
87
-10
-10% -$941 ﹤0.01% 787
2023
Q1 		$1.39K Sell
97
-6
-6% -$622 0.04% 333
2022
Q4 		$1.39K Sell
103
-917
-90% -$86.1K 0.01% 603
2022
Q3 		$1.22K Buy
1,020
+24
+2% +$2.14K 0.04% 337
2022
Q2 		$1.19K Buy
996
+72
+8% +$5.73K 0.04% 308
2022
Q1 		$1.11K Sell
924
-220
-19% -$18.4K 0.03% 329
2021
Q4 		$1.27K Buy
1,144
+1,130
+8,071% +$93.2K 0.03% 365
2021
Q3 		$77K Hold
14
– – 0.04% 430
2021
Q2 		$83K Sell
14
-8
-36% -$634 0.03% 404
2021
Q1 		$1.67K Sell
22
-66
-75% -$5.39K 0.03% 250
2020
Q4 		$8K Buy
+88
New +$6.98K 0.01% 193
2020
Q2 		– Sell
-574
Closed -$48.5K – 119
2020
Q1 		$48.5K Sell
574
-398
-41% -$34.3K 0.15% 69
2019
Q4 		$85K Sell
972
-488
-33% -$36.9K 0.06% 389
2019
Q3 		$98K Sell
1,460
-330
-18% -$25.4K 0.08% 211
2019
Q2 		$153K Sell
1,790
-377
-17% -$32.3K 0.13% 178
2019
Q1 		$194K Buy
+2,167
New +$201K 0.16% 140
2018
Q3 		$195K Sell
2,081
-101
-5% -$10.1K 0.2% 122
2018
Q2 		$221K Sell
2,182
-185
-8% -$16.2K 0.21% 97
2018
Q1 		$195K Buy
+2,367
New +$203K 0.2% 96

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Financial Gravity Asset Management's BMRN Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 24 shares — an estimated $2.18K sold.

Financial Gravity Asset Management first reported a position in BMRN in Q1 2018 and held it in 22 quarters. The position peaked at $221K in Q2 2018. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 24 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $2.18K.
  • Financial Gravity Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 22 quarters.
  • Financial Gravity Asset Management's BioMarin Pharmaceuticals position peaked at $221K in Q2 2018.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.